About
Technology
Issues
FAQ
Links
Official Page
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.